Envíos recientes

Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy

Somara, Sasikala; Ko, Heidi; Thatai, Purva; Wallen, Zachary; Saini, Kamal S.; Quintana, Angela (Frontiers Media, 2024-10-08)

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Verlingue, Loic; Prenen, Hans; Guerra Alia, Eva Maria; Tosi, Diego; ITALIANO, ANTOINE; Perets, Ruth; OAKNIN, ANA (Elsevier, 2024-11)

Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar

Amellal, Nadia Causse; Calleja, Edward; Fakih, Marwan; Prager, M.D., Gerald; Tabernero, Josep; taieb, julien (Elsevier, 2024-11)

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

Accordino, Melissa; Gambardella, Valentina; Jhaveri, Komal; Bedard, Philippe; Cervantes, Andrés; Hamilton, Erika; Oliveira, Mafalda; Saura Manich, Cristina (American Society of Clinical Oncology, 2024-11-20)

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial

Murphy, Danielle A.; Pu, Jie; Kopetz, Scott; Ciardiello, Fortunato; Desai, Jayesh; Van Cutsem, Eric; Tabernero, Josep (Nature Portfolio, 2024-11)

Scientia. Depósito de Información Digital del Departamento de Salud

VHIO - Articles científics: Envíos recientes

Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial

Scientia. Depósito de Información Digital del Departamento de Salud

VHIO - Articles científics: Envíos recientes

Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy ﻿

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma ﻿

Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar ﻿

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer ﻿

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial ﻿

Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy

Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma

Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial